Abstract
Azacitidine (AZA), the reference treatment for most higher-risk myelodysplastic (MDS) patients can also improve overall survival (OS) in elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, but reliable biological markers predicting response and OS in patients treated with AZA are lacking. In a preliminary study, we found that an increase of the percentage of BCL2L10, an anti-apoptotic member of the bcl-2 family, was correlated with AZA resistance. In this study, we assessed prospectively by flow cytometry the prognostic value of BCL2L10 positive bone marrow mononuclear cells in 70 patients (42 MDS and 28 AML), prior to AZA treatment.In patients with baseline marrow blasts below 30%, the baseline percentage of bone marrow BCL2L10 positive cells inversely correlated with response to AZA and OS independently of the International Prognostic Scoring System (IPSS) and IPSS-revised (IPSS-R). Specifically, OS was significantly lower in patients with more than 10% BCL2L10 positive cells (median 8.3 vs 22.9 months in patients with less than 10% positivity, p = 0,001). In summary, marrow BCL2L10 positive cells may be a biomarker for azacitidine response and OS, with a potential impact in clinical practice.
References
Mar 30, 2001·The Journal of Biological Chemistry·N KeJ C Reed
Aug 19, 2003·The Biochemical Journal·Dayong ZhaiJohn C Reed
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Feb 20, 2004·Cancer Research·Kohichiroh YasuiJohji Inazawa
Apr 13, 2006·Blood·Bruce D ChesonHagop Kantarjian
Jan 18, 2007·Blood·Frederic LucianoJohn C Reed
Feb 24, 2009·The Lancet Oncology·Pierre FenauxUNKNOWN International Vidaza High-Risk MDS Survival Study Group
Oct 14, 2010·Blood·Raphael ItzyksonUNKNOWN Groupe Francophone des Myelodysplasies(GFM)
Nov 17, 2010·American Journal of Hematology·Mikkael A SekeresJaroslaw P Maciejewski
Feb 5, 2011·Oncotarget·Emmanuel RaffouxHervé Dombret
Apr 16, 2011·Leukemia·R ItzyksonUNKNOWN Groupe Francophone des Myelodysplasies (GFM)
Jan 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Levi J BeverlyHarold Varmus
May 12, 2012·Oncotarget·Thomas CluzeauPatrick Auberger
Dec 18, 2012·Blood·Mathilde LamarqueLionel Adès
Jun 7, 2013·Annals of Hematology·María AbáigarJesús María Hernández-Rivas
Nov 5, 2013·Blood Cancer Journal·T CluzeauS Raynaud
Apr 10, 2014·British Journal of Haematology·Amer M ZeidanUNKNOWN Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup
May 20, 2014·Leukemia Research·Cecile BallyPierre Fenaux
Sep 17, 2014·Blood·Rafael BejarBenjamin L Ebert
Jan 13, 2015·Cancer Science·Tomoko HyodaKaoru Tohyama
Mar 31, 2015·The Journal of Clinical Investigation·Kristen MeldiMaria E Figueroa
May 20, 2015·Blood·Hervé DombretHartmut Döhner
Citations
Dec 8, 2017·American Journal of Hematology·Guillermo Montalban-Bravo, Guillermo Garcia-Manero
Nov 14, 2019·Leukemia·Guillermo Montalban-BravoGuillermo Garcia-Manero
Jan 25, 2019·Oncology Letters·Hongbin LiuAnthony E Dear
Jun 13, 2020·Blood Cancer Journal·Albin ÖsterroosSören Lehmann
Oct 19, 2019·Cells·Guillaume RobertPatrick Auberger
Aug 8, 2018·Annals of Hematology·Hong WangLi Yu
Aug 4, 2020·Cancer Biomarkers : Section a of Disease Markers·Yangli ZhaoJingdong Zhou
Jun 4, 2019·Therapeutic Advances in Hematology·Angela Gil-Perez, Guillermo Montalban-Bravo
Dec 29, 2020·Cancer Biology & Therapy·Govind BabuPradip K Majumder
Apr 11, 2021·Expert Opinion on Investigational Drugs·Talha Badar, Ehab Atallah
May 8, 2021·Leukemia·Julia StomperMichael Lübbert